Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study

May 01 2012

• By Emily Hayes

Related Content

Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors

Nov 08 2010

FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option

Oct 20 2010

<em>Xarelto</em> Filing Puts It Out Ahead In Venous Thromboembolism

May 02 2012

Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Nov 07 2011

Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?

Aug 29 2011

<em>Eliquis</em> Delay Fuels Speculation About Advisory Committee Meeting

Mar 01 2012

<em>Xarelto</em> Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed

May 01 2012

Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label

Apr 02 2012

FDA Approval Of <i>Xarelto</i> Bodes Well For Drug’s Future Expansion

Jul 11 2011

Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes

Dec 07 2011

Related Companies

Boehringer Ingelheim GmbH

Johnson & Johnson

Bayer AG

Bristol Myers Squibb Company

Pfizer Inc.

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window